Here is the design of a clinical trial:

Official Title: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)

Included conditions:
- Pulmonary Infection
- Covid-19

Study Armgroups:
- {'label': 'T3 solution for injection', 'type': 'EXPERIMENTAL', 'description': 'T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).', 'interventionNames': ['Drug: T3 solution for injection']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Composition identical apart from the active substance. Same dosage.', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'T3 solution for injection', 'description': 'For example, for a patient of 77Kg of weight, a dose of 6ml (60 μg) will be administered as a bolus intravenously over 2-3 min within 60 min of respiratory support initiation. Then, the patient for the next 24 hours will receive 21ml of the product (total of 210 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 10.4 ml/h for a total duration of 48 hours. From day 3 till successful weaning or end of follow-up, the patient will receive 50% of this dose, 10.5 ml of the product (total of 105 μg of T3) that will be diluted in NaCl 0.9% and administered with a pump at a steady flow rate of 5.2 ml/h.', 'armGroupLabels': ['T3 solution for injection']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'Same as with T3 solution for injection.', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': 'Assessment of weaning from cardiorespiratory support', 'description': 'The primary objective of the study is to determine whether the administration of intravenous triiodothyronine in ICU patients diagnosed with pulmonary infection due to COVID-19 facilitates weaning from cardiorespiratory support compared to placebo. Successful weaning is defined as no requirement for ventilatory support after extubation (mechanical support) or support from ECMO for 48 hours. The primary objective will be measured as percentage of patients successfully weaned after 30 days of follow-up.', 'timeFrame': '30 days'}

Please estimate the sample size based on the assumption: 
84% power, significance level (alpha) of 0.05, 2-tailed test
Numbers to be randomised (sample size)
          The sample size of 60 patients (that indicates 30 subjects for each group) will have 84% power to detect the estimated difference between the two study groups. The criterion for significance (alpha) has been set at 0.05 and the test is 2-tailed.